GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (OTCPK:TLIS) » Definitions » Insider Ownership

TLIS (Talis Biomedical) Insider Ownership : 18.26 % (As of Apr. 29, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Talis Biomedical's insider ownership is 18.26%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Talis Biomedical's Institutional Ownership is 13.65%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Talis Biomedical's Float Percentage Of Total Shares Outstanding is 63.91%.


Talis Biomedical Insider Ownership Historical Data

The historical data trend for Talis Biomedical's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talis Biomedical Insider Ownership Chart

Talis Biomedical Historical Data

The historical data trend for Talis Biomedical can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Insider Ownership 18.27 18.27 18.26 18.26 18.26 18.26 18.26 18.26 18.26 18.26

Talis Biomedical Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Talis Biomedical Business Description

Traded in Other Exchanges
N/A
Address
1375 West Fulton Market, Suite 700, Chicago, IL, USA, 60607
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
Executives
Andrew A Lukowiak officer: President, other: Chief Scientific Officer 1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich officer: Interim CFO CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser director, officer: President and CEO 561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan officer: Sr. Vice President, R&D 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Moody John Roger Jr officer: Chief Financial Officer 4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062